Download MendeleyA broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch.
Wang, Z., Barnes, C.O., Gautam, R., Cetrulo Lorenzi, J.C., Mayer, C.T., Oliveira, T.Y., Ramos, V., Cipolla, M., Gordon, K.M., Gristick, H.B., West, A.P., Nishimura, Y., Raina, H., Seaman, M.S., Gazumyan, A., Martin, M., Bjorkman, P.J., Nussenzweig, M.C., Escolano, A.(2020) Elife 9
- PubMed: 33084569 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.7554/eLife.61991
- Primary Citation Related Structures:
7KDE - PubMed Abstract:
A small fraction of HIV-1- infected humans develop broadly neutralizing antibodies (bNAbs) against HIV-1 that protect macaques from simian immunodeficiency HIV chimeric virus (SHIV). Similarly, a small number of macaques infected with SHIVs develop broadly neutralizing serologic activity, but less is known about the nature of simian antibodies. Here, we report on a monoclonal antibody, Ab1485, isolated from a macaque infected with SHIVAD8 that developed broadly neutralizing serologic activity targeting the V3-glycan region of HIV-1 Env. Ab1485 neutralizes 38.1% of HIV-1 isolates in a 42-pseudovirus panel with a geometric mean IC50 of 0.055 µg/mLl and SHIVAD8 with an IC50 of 0.028 µg/mLl. Ab1485 binds the V3-glycan epitope in a glycan-dependent manner. A 3.5 Å cryo-electron microscopy structure of Ab1485 in complex with a native-like SOSIP Env trimer showed conserved contacts with the N332gp120 glycan and gp120 GDIR peptide motif, but in a distinct Env-binding orientation relative to human V3/N332gp120 glycan-targeting bNAbs. Intravenous infusion of Ab1485 protected macaques from a high dose challenge with SHIVAD8. We conclude that macaques can develop bNAbs against the V3-glycan patch that resemble human V3-glycan bNAbs.
- Laboratory of Molecular Immunology, The Rockefeller University, New York, United States.
Organizational Affiliation:
